Progress in Therapy of Parkinson's Disease and Related Diseases
|
Accession number;06A0654484
|
| Title;Progress in Therapy of Parkinson's Disease and Related Diseases |
| Author;
KONDO TOMOYOSHI
(Fac. Medicine, Wakayama Medical Univ., JPN)
|
Journal Title;Neurological Therapeutics
|
Journal Code:X0110A
|
ISSN:0916-8443
|
|
VOL.23;NO.4;PAGE.373-376(2006)
|
| Figure&Table&Reference;REF.14 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The author reviews the advances in the therapy of Parkinson's disease (PD) in 2005. Levodopa: Several studies of levodopa therapy are reviewed. 1) PD patients have a low threshold for pain, and sensation normalization by levodopa therapy was demonstrated using positron emission tomography. 2) The author is interested in the term of "levodopa phobia" in a short communication of a journal. There is a poor control of parkinsonism due to the patients' fear of taking levodopa, which originated from an excessive propagation of an unconfirmed hypothesis that levodopa is toxic. 3) The biological availability of levodopa is decreased by 50% following the ingestion of banana, because banana contains polyphenoloxides that oxidize levodopa. Some patients eating banana as a measure to control constipation should be a concern. MAO-B inhibitors and COMT inhibitor: Regarding drugs modifying levodopa or dopamine metabolism, results of the meta-analysis of the Cochrane Library of the data of monomamine oxidase-B (MAO-B) inhibitors and an investigation on the drug formulation (individual tablets or compound tablets with levodopa) of a catechol-o-methyl transferase (COMT) inhibitor were reported. MAO-B inhibitors decrease the Unified PD Rating Scale score and dose of levodopa, improve the activity of daily living, and attenuate the wearing off phenomenon, which is a symptomatic effect. Dopamine agonists: Regarding dopamine agonist (DA) therapy, studies of the transdermal delivery of DA, high-dose pergolide therapy, the incidence of pathological gambling under pramipexole, and the effect of pramipexole on anhedonia are reviewed. Atypical antipsychotics: A double-blind placebo controlled study showed that quetiapine does not improve drug-induced hallucination. (author abst.) |
|
|
|
Related Articles;
|
|
